0.4972
price down icon7.72%   -0.0416
 
loading
前日終値:
$0.5388
開ける:
$0.54
24時間の取引高:
2.29M
Relative Volume:
2.90
時価総額:
$38.64M
収益:
$8.23M
当期純損益:
$-32.49M
株価収益率:
-0.9381
EPS:
-0.53
ネットキャッシュフロー:
$-19.91M
1週間 パフォーマンス:
+21.56%
1か月 パフォーマンス:
-40.81%
6か月 パフォーマンス:
-46.54%
1年 パフォーマンス:
-56.00%
1日の値動き範囲:
Value
$0.48
$0.547
1週間の範囲:
Value
$0.292
$0.60
52週間の値動き範囲:
Value
$0.292
$1.65

Clearside Biomedical Inc Stock (CLSD) Company Profile

Name
名前
Clearside Biomedical Inc
Name
セクター
Healthcare (1164)
Name
電話
678-270-3631
Name
住所
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Name
職員
32
Name
Twitter
@clearsidebio
Name
次回の収益日
2025-03-18
Name
最新のSEC提出書
Name
CLSD's Discussions on Twitter

CLSD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CLSD
Clearside Biomedical Inc
0.4972 41.87M 8.23M -32.49M -19.91M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-18 ダウングレード Chardan Capital Markets Buy → Neutral
2025-07-18 ダウングレード H.C. Wainwright Buy → Neutral
2025-07-18 ダウングレード Stifel Buy → Hold
2024-08-21 開始されました Chardan Capital Markets Buy
2024-06-25 開始されました Oppenheimer Outperform
2021-12-15 再開されました Wedbush Outperform
2021-07-29 開始されました H.C. Wainwright Buy
2020-05-13 開始されました ROTH Capital Buy
2019-08-09 ダウングレード Needham Buy → Hold
2018-11-05 ダウングレード Cowen Outperform → Market Perform
2018-11-05 ダウングレード JP Morgan Overweight → Underweight
2018-11-05 ダウングレード Stifel Buy → Hold
2018-03-06 繰り返されました Needham Buy
2017-05-25 開始されました JMP Securities Mkt Outperform
2017-02-24 開始されました JP Morgan Overweight
2016-11-10 繰り返されました Needham Buy
2016-10-24 繰り返されました Stifel Buy
すべてを表示

Clearside Biomedical Inc (CLSD) 最新ニュース

pulisher
Jul 25, 2025

Clearside Biomedical’s Phase 2b Study on CLS-AX: A New Hope for AMD Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Clearside Biomedical Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Clearside Biomedical Inc. stockBreakthrough stock performance - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Why Clearside Biomedical Inc. stock attracts strong analyst attentionFree Stock Market Analysis Courses - Newser

Jul 24, 2025
pulisher
Jul 24, 2025

Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal Delivery - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Clearside Biomedical Announces Approval of XIPERE® - GlobeNewswire

Jul 24, 2025
pulisher
Jul 23, 2025

Clearside Biomedical announces approval of XIPERE in Canada - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Is Clearside Biomedical Inc. a good long term investmentExceptional portfolio growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Clearside Biomedical stock soars after Health Canada approves XIPERE - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Clearside Biomedical stock soars after Health Canada approves XIPERE By Investing.com - Investing.com South Africa

Jul 23, 2025
pulisher
Jul 23, 2025

Health Canada approves Clearside’s XIPERE for uveitic macular edema By Investing.com - Investing.com Nigeria

Jul 23, 2025
pulisher
Jul 23, 2025

Health Canada approves Clearside’s XIPERE for uveitic macular edema - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Breakthrough Eye Treatment XIPERE Secures Major Health Canada Approval for Macular Edema - Stock Titan

Jul 23, 2025
pulisher
Jul 22, 2025

Clearside Biomedical Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Clearside exploring options to advance suprachoroidal delivery platform - Eyes On Eyecare

Jul 22, 2025
pulisher
Jul 22, 2025

Clearside Biomedical announces plan to explore strategic alternatives to advance its proprietary suprachoroidal space (SCS) delivery platform and promising ophthalmology pipeline - Eyes On Eyecare

Jul 22, 2025
pulisher
Jul 21, 2025

Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Target Price at $4.20 - Defense World

Jul 21, 2025
pulisher
Jul 21, 2025

Uncovering the Potential of Clearside Biomedical Inc (CLSD) Stock - investchronicle.com

Jul 21, 2025
pulisher
Jul 21, 2025

Clearside Biomedical (NASDAQ:CLSD) Downgraded by Stifel Nicolaus to "Hold" - MarketBeat

Jul 21, 2025
pulisher
Jul 20, 2025

Chardan Capital Downgrades Clearside Biomedical (NASDAQ:CLSD) to Neutral - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

What institutions are buying Clearside Biomedical Inc. stock nowFree Stock Trading Signals - beatles.ru

Jul 19, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 21:44:13 - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Health Care Stocks Stumble As Sector Faces Fresh Setbacks - Finimize

Jul 18, 2025
pulisher
Jul 18, 2025

Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 22:42:56 - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

A Quick Look at Today's Ratings for Clearside Biomedical(CLSD.US), With a Forecast Between $0.84 to $3 - 富途牛牛

Jul 18, 2025
pulisher
Jul 18, 2025

Clearside Biomedical downgraded to Neutral from Buy at Chardan - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

CLSD: Downgraded to Neutral by HC Wainwright & Co. | CLSD Stock News - GuruFocus

Jul 18, 2025
pulisher
Jul 18, 2025

Why Clearside Biomedical Inc. stock is on top investor watchlistsHigh Return Stock Alerts - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Chardan Capital downgrades Clearside Biomedical stock rating to Neutral By Investing.com - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

Chardan Capital downgrades Clearside Biomedical stock rating to Neutral - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Stifel downgrades Clearside Biomedical stock to Hold on cash concerns By Investing.com - Investing.com Nigeria

Jul 18, 2025
pulisher
Jul 18, 2025

Stifel downgrades Clearside Biomedical stock to Hold on cash concerns - Investing.com Australia

Jul 18, 2025

Clearside Biomedical Inc (CLSD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Clearside Biomedical Inc (CLSD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Chong Ngai Hang Victor
Chief Medical Officer
Nov 01 '24
Buy
1.00
36,500
36,500
100,000
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):